Top Markets
Coin of the day
Aardvark Therapeutics, Inc. Common Stock Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. Common Stock

AARD
Hisse Senetlerindeki Sıralama #19548
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical... Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Hisse Fiyatı
$7.22
Son senkronizasyon: 2026-08-25
Piyasa Değeri
$158.03M
Değişim (1 gün)
4.96%
Değişim (1 yıl)
-24.22%
Ülke
US
Ticaret Aardvark Therapeutics, Inc. Common Stock (AARD)

Kategori

Aardvark Therapeutics, Inc. Common Stock (AARD) için P/S oranı
2026 itibarıyla P/S oranı TTM: 0
Aardvark Therapeutics, Inc. Common Stock şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/S oranı 0 idi.
Aardvark Therapeutics, Inc. Common Stock için P/S oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/S oranı
Yıl P/S Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/S oranı
Şirket P/S Oranı P/S Oranı Farkı Ülke
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH